Pharmaceuticals

A new Concord research center combines patient care and clinical trials, promising to speed up breakthroughs for complex heart, kidney, and metabolic diseases.

A novel triple-action topical spray for male pattern baldness enters a pivotal clinical trial, potentially disrupting a multi-billion dollar market.

Lipocine's stock plummets after its PPD drug fails a Phase 3 trial, but a promising signal in a patient subset offers a narrow path forward.

AvenCell has dosed the first patient with AVC-203, a novel allogeneic CAR-T therapy, aiming to make advanced cancer treatment more accessible and effective.

Scientists propose a unifying model combining 'viral mimicry' and 'cancer dark matter,' potentially revolutionizing how our immune system recognizes and fights tumors.

Indian pharma giant Lupin acquires European ophthalmology specialist VISUfarma, gaining a major foothold in a market fueled by an aging population.

With key hires from Flatiron and Syneos, Target RWE signals major scaling plans in the booming real-world evidence market under new ownership.

With a new patent for its drug ALPHA-1062, Alpha Cognition may become a first-mover in the $14 billion traumatic brain injury market, which has no approved therapies.

A new partnership aims to simplify pharmacy savings by combining a navigation hub with an AI-powered marketplace, challenging traditional industry models.

A novel transdermal curcumin gel shows significant pain reduction in a clinical trial, offering a potential non-oral alternative for millions with knee pain.

With a key data readout looming for its chronic cough drug, Nocion adds a renowned dealmaker to its board, fueling speculation of a potential acquisition.

With a unique drug that preserves muscle while shedding fat, a newly fortified biotech is set to challenge the titans of the weight-loss market.

A new investigation shows drug companies make $31 in profit for every $1 paid in penalties, suggesting fines are just a cost of doing business.

As regulators demand PBM reform, Liviniti marks 15 years and 1 million members served with its pioneering transparent, pass-through pricing model.

Veteran biotech CEO Paul Sekhri joins investor Petrichor, signaling a strategic shift where hands-on leadership is now paramount in life sciences investing.

Biotech veteran Dr. Vince O'Neill joins Mosaic Therapeutics to spearhead its synergistic precision oncology pipeline, aiming to transform cancer treatment.

Parnell’s nixiFLOR, the first generic of Resflor Gold®, offers a cost-effective new weapon for ranchers battling Bovine Respiratory Disease.

As China surpasses the US in key research metrics, a new English platform aims to bridge the information gap for global scientists and innovators.

A stark new benchmark study reveals poor survival in late-stage GvHD, just as MaaT Pharma’s microbiome therapy shows dramatically better outcomes.

Abbisko's irpagratinib gets EMA Orphan Drug status, fast-tracking a precision therapy for a hard-to-treat liver cancer subgroup with unmet needs.